Airsonett's TLA technology is now included in the guidelines for treatment of severe asthma in the South Swedish national health care
National health care in the South Swedish region of Skåne has updated its guidelines for treatment of patients with severe allergic asthma. Airsonett and the treatment with the TLA technology (Temperature-controlled laminar airflow) has been given its own guidelines based on the primary indication to prevent asthma attacks (exacerbations). The guidelines have been established by the Director of Health Care in Region Skåne.
Treatment with Airsonett TLA can be prescribed in Region Skåne by doctors specializing in allergy-, lung-, or child medicine and experience of treatment of severe asthma.
For complete guidelines of Airsonett TLA, Region Skåne:
”Airsonett and treatment with TLA have been included in the national guidelines for asthma treatment since 2015. The fact that Region Skåne now introduces its own guidelines for Airsonett TLA is further proof of the positive effect the treatment has on patients with severe allergic asthma”, says Anders Due-Boje, CEO Airsonett AB.
About severe, uncontrolled asthma
Patients with severe, uncontrolled asthma treated according to Global Initiative for Asthma (GINA) step 4/5 account for approximately 3% of all patients with persistent asthma, according to recent population-based studies using administrative and prescribed databases, but account for a much larger share of asthma-related healthcare resource use and costs. Treatment alternatives for such patients include high-dose inhaled corticosteroids (ICS) and long-acting β2-antagonists (LABAs) and/or systematic corticosteroids. During the last decade, several new drugs for the treatment of severe asthma have been developed,and some of these drugs, such as anti-immunoglobulin E and anti-interleukin 5 have been included in Step 5 in the latest GINA recommendations. The costs for treatment with these biologics are however very high. Temperature-controlled laminar airflow (TLA) is a relatively new treatment for patients with severe, uncontrolled asthma. The use of TLA has shown cost-effectiveness according to National Institute for Health and Care Excellence (NICE) standards and the Swedish Dental and Pharmaceutical Benefits Agency, TLV, a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state.
For more information:
Anders Due-Boje, CEO, Airsonett AB
Tel: +46 70 526 03 00
Airsonett® is a Swedish medical device company that leads the way in the development of non-pharmacologic treatment of allergic severe asthma and eczema. Airsonett®Air4 is a non-invasive device for treatment in the home, based on the patented Temperature-controlled Laminar Airflow technology (TLA). Treatment with the Airsonett®Air4 significantly reduces allergens and other airborne irritants from the patient’s breathing zone during rest and sleep.Airsonett®Air4 is a CE marked class 1 medical device intended to be used for the alleviation of symptoms of allergy-induced diseases such as allergic asthma and eczema. It adheres to relevant EU directives regarding design, function, safety and health requirements and has undergone rigorous clinical research as well as health-economic studies. Airsonett®Air4 holds a 510(k) cleared class II approval from FDA. The company’s main shareholders are SEB Venture Capital, Industrifonden and Magnus Lundberg. For more information, visit www.airsonett.eu
Please visit https://airsonett.eu/clinical-evidence/for an overview of the clinical documentation of Airsonett Air4 and the TLA-technology.